{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:14Z","timestamp":1792791494040,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patent ductus arteriosus (PDA) is common in preterm infants. Although pharmacologic treatment promotes ductal closure, its impact on clinically meaningful outcomes remains uncertain. This study aimed to evaluate the association between different pharmacologic PDA treatment strategies and major neonatal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included preterm infants born at &amp;lt;32 weeks\u2019 gestation who received pharmacologic treatment for clinically significant PDA following an integrated echocardiographic and clinical assessment in a tertiary-level neonatal intensive care unit between 2018 and 2024. Infants were categorized by treatment strategy (ibuprofen only, paracetamol only, or sequential therapy), treatment timing, and number of treatment courses. The primary outcome was a composite of bronchopulmonary dysplasia (BPD) and\/or mortality. Secondary outcomes included intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, and sepsis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 76 preterm infants were included, with a median gestational age of 28 weeks (IQR 26\u201330) and mean birth weight of 1,076\u2009\u00b1\u2009343\u2005g. Infants were treated with ibuprofen only (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931, 40.8%), paracetamol only (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927, 35.5%), or sequential therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918, 23.7%). The composite outcome occurred in 39 infants (51.3%) and did not differ significantly across treatment groups. In multivariate analysis, gestational age emerged as the strongest independent predictor of BPD and\/or mortality (adjusted OR 0.54, 95% CI 0.38\u20130.77;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), while treatment category was not independently associated with outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacologic PDA treatment strategies were not independently associated with BPD and\/or mortality in this retrospective cohort. Gestational age showed the strongest association with the primary outcome; however, residual confounding and limited statistical power preclude causal or equivalence conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1888603","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:30Z","timestamp":1783575330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic treatment strategies and association with major neonatal outcomes for patent ductus arteriosus in preterm infants"],"prefix":"10.3389","volume":"14","author":[{"given":"Ercan","family":"Tutak","sequence":"first","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimet","family":"C\u0131nd\u0131k","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, Department of Pediatrics, Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eser","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, Department of Pediatrics, Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Emre","family":"Ayhan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"\u00d6zer","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","year":"","DOI":"10.1542\/peds.2020-1209"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1542\/neo.19-7-e394","article-title":"Diagnosis and management of patent ductus arteriosus","volume":"19","author":"Gillam-Krakauer","year":"2018","journal-title":"Neoreviews"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e20153730","DOI":"10.1542\/peds.2015-3730","article-title":"Patent ductus arteriosus in preterm infants","volume":"137","author":"Benitz","year":"2016","journal-title":"Pediatrics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/jp.2010.3","article-title":"Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?","volume":"30","author":"Benitz","year":"2010","journal-title":"J Perinatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jpeds.2015.03.012","article-title":"Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia","volume":"166","author":"Schena","year":"2015","journal-title":"J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.clp.2020.05.007","article-title":"Patent ductus arteriosus\u2014time for a definitive trial","volume":"47","author":"Mitra","year":"2020","journal-title":"Clin Perinatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD003481","DOI":"10.1002\/14651858.CD003481.pub8","article-title":"Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants","volume":"2","author":"Ohlsson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013278.pub3","article-title":"Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants","author":"Mitra","year":"","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1080\/14767058.2017.1338263","article-title":"Paracetamol versus ibuprofen for the treatment of patent ductus arteriosus in preterm neonates: a meta-analysis of randomized controlled trials","volume":"31","author":"Huang","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00431-016-2830-7","article-title":"Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates","volume":"176","author":"El-Mashad","year":"2017","journal-title":"Eur J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jpeds.2013.11.008","article-title":"Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial","volume":"164","author":"Oncel","year":"2014","journal-title":"J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00431-025-06130-8","article-title":"Heterogeneity in treatment response for patent ductus arteriosus: a meta-analysis","volume":"184","author":"Matsushita","year":"2025","journal-title":"Eur J Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.gpeds.2023.100128","article-title":"Patent ductus arteriosus (PDA): recent recommendations to close or not to close","volume":"7","author":"K\u00f6stekci","year":"2024","journal-title":"Glob. Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa2305582","article-title":"Trial of selective early treatment of patent ductus arteriosus with ibuprofen","volume":"390","author":"Gupta","year":"2024","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","year":"","DOI":"10.1056\/NEJMoa2207418"},{"key":"B16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1084-2756(02)00192-6","article-title":"Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition","volume":"8","author":"Bancalari","year":"2003","journal-title":"Semin Neonatol"},{"key":"B17","first-page":"777","article-title":"Preterm intraventricular hemorrhage\/posthemorrhagic hydrocephalus","volume-title":"Volpe's Neurology of the Newborn","author":"Inder","year":"2024"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000658-197801000-00001","article-title":"Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging","volume":"187","author":"Bell","year":"1978","journal-title":"Ann Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41390-025-03820-9","article-title":"Beneficial vs harmful effects of pharmacological treatment of patent ductus arteriosus: a Bayesian meta-analysis","volume":"98","author":"Villamor","year":"2025","journal-title":"Pediatr Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101473","DOI":"10.1016\/j.siny.2024.101473","article-title":"Pharmacological treatment of patent ductus arteriosus in preterm infants: benefits, risks, and clinical trade-offs","volume":"30","author":"Buvaneswarran","year":"2025","journal-title":"Semin Fetal Neonatal Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1111\/bcp.15291","article-title":"Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: a systematic review and meta-analysis of randomized controlled trials","volume":"88","author":"Katsaras","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101677","DOI":"10.1016\/j.jnn.2025.101677","article-title":"Paracetamol versus ibuprofen as first-line treatment for patent ductus arteriosus: an updated systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Windiana","year":"2025","journal-title":"J Neonatal Nurs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e20240058","DOI":"10.36660\/abc.20240058","article-title":"Therapeutic efficacy and safety of paracetamol versus ibuprofen in patent ductus arteriosus in newborns: a systematic review","volume":"121","author":"da Silva","year":"2024","journal-title":"Arq Bras Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"F94","DOI":"10.1136\/archdischild-2012-302044","article-title":"An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants","volume":"98","author":"Oncel","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000456073","article-title":"Paracetamol in patent ductus arteriosus treatment: efficacious and safe?","volume":"111","author":"Sallmon","year":"2017","journal-title":"Neonatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2023065056","DOI":"10.1542\/peds.2023-065056","article-title":"Acetaminophen For patent ductus arteriosus and risk of mortality and pulmonary morbidity","volume":"154","author":"Jensen","year":"2024","journal-title":"Pediatrics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"106167","DOI":"10.1016\/j.earlhumdev.2024.106167","article-title":"Effectiveness of repeated pharmacological courses for patent ductus arteriosus in preterm infants","volume":"200","author":"Dani","year":"2025","journal-title":"Early Hum Dev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/children12050577","article-title":"Second attempt for patent ductus arteriosus (PDA) closure: room for Acetaminophen? A retrospective single-center experience at gaslini Children's Hospital","volume":"12","author":"Caruggi","year":"2025","journal-title":"Children"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1055\/a-1782-5860","article-title":"Randomized noninferiority trial of expectant management versus early treatment of patent ductus arteriosus in preterm infants","volume":"39","author":"Potsiurko","year":"2022","journal-title":"Am J Perinatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2025071425","DOI":"10.1542\/peds.2025-071425","article-title":"Patent ductus arteriosus in preterm infants","volume":"155","author":"Ambalavanan","year":"2025","journal-title":"Pediatrics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapediatrics.2025.1025","article-title":"Active treatment vs expectant management of patent ductus arteriosus in preterm infants: a meta-analysis","volume":"179","author":"Buvaneswarran","year":"2025","journal-title":"JAMA Pediatr"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1888603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:31Z","timestamp":1783575331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1888603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":32,"alternative-id":["10.3389\/fped.2026.1888603"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1888603","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1888603"}}